Community Practice Connections : Oncology Best Practice Decision Points in Advanced NSCLC : Assessing Treatment Options Beyond Disease Progression
WebcastFaculty
OVERVIEW
Community Practice Connections : Oncology Best Practice Decision Points in Advanced NSCLC : Assessing Treatment Options Beyond Disease Progression is organized by Physicians Education Resource, LLC (PER) and will be held during Nov 30, 2017 - Nov 30, 2018.
The target audience for this medical event is directed toward oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.
Course Description :
The management of patients with advanced non-small cell lung cancer (NSCLC) who have progressed following prior-platinum-based therapies represents an important educational need among practitioners who care for patients with lung cancer. Although our improved understanding of actionable tumor characteristics has assisted to inform clinical decision-making concerning the use of certain targeted agents, treatment selection for patients who have progressed but who do not have activating mutations is more complex. Clinical status and biomarker information may be used to inform therapeutic selection, but it is also important that practitioners understand results from key trials that have been conducted in patients who have progressed on or after platinum-based approaches. Current treatment options in this regard include immune checkpoint inhibitors, single agent chemotherapy, ramucirumab plus docetaxel, and EGFR tyrosine-kinase inhibitors.
This is an area in lung cancer treatment for which there have been multiple therapeutic developments in recent years. As new biomarkers and patient characteristics continue to emerge that assist clinicians to predict responsiveness to particular approaches, practitioners will need updates that allow them optimize outcomes in these most difficult-to-treat settings of lung cancer management. Education in this regard should focus on the evidence that informs therapeutic selection in post-platinum treated relapsed advanced NSCLC, circumstances that should guide switching of therapies, and methods to proactively manage treatment-related adverse events.
Learning Objectives :
At the conclusion of this activity, you should be better prepared to:
• Assess testing methods that should be applied to inform clinical decision-making for patients with advanced NSCLC who have progressed following platinum-based chemotherapy
• Describe landmark clinical trials that have evaluated patients with advanced NSCLC who have progressed on platinum-based therapeutic approaches
• Explain strategies to proactively address treatment-related adverse events in patients with advanced NSCLC
• Construct an algorithm based on clinical and biomarker information for the management of patients who have progressed following platinum-based chemotherapy in either front-line treatment or following front-line immunotherapy
Additional details will be posted as soon as they are available.
The target audience for this medical event is directed toward oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.
Course Description :
The management of patients with advanced non-small cell lung cancer (NSCLC) who have progressed following prior-platinum-based therapies represents an important educational need among practitioners who care for patients with lung cancer. Although our improved understanding of actionable tumor characteristics has assisted to inform clinical decision-making concerning the use of certain targeted agents, treatment selection for patients who have progressed but who do not have activating mutations is more complex. Clinical status and biomarker information may be used to inform therapeutic selection, but it is also important that practitioners understand results from key trials that have been conducted in patients who have progressed on or after platinum-based approaches. Current treatment options in this regard include immune checkpoint inhibitors, single agent chemotherapy, ramucirumab plus docetaxel, and EGFR tyrosine-kinase inhibitors.
This is an area in lung cancer treatment for which there have been multiple therapeutic developments in recent years. As new biomarkers and patient characteristics continue to emerge that assist clinicians to predict responsiveness to particular approaches, practitioners will need updates that allow them optimize outcomes in these most difficult-to-treat settings of lung cancer management. Education in this regard should focus on the evidence that informs therapeutic selection in post-platinum treated relapsed advanced NSCLC, circumstances that should guide switching of therapies, and methods to proactively manage treatment-related adverse events.
Learning Objectives :
At the conclusion of this activity, you should be better prepared to:
• Assess testing methods that should be applied to inform clinical decision-making for patients with advanced NSCLC who have progressed following platinum-based chemotherapy
• Describe landmark clinical trials that have evaluated patients with advanced NSCLC who have progressed on platinum-based therapeutic approaches
• Explain strategies to proactively address treatment-related adverse events in patients with advanced NSCLC
• Construct an algorithm based on clinical and biomarker information for the management of patients who have progressed following platinum-based chemotherapy in either front-line treatment or following front-line immunotherapy
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links